Visual Acuity

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.

Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert.

KOLOA, Hawaii — Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025.

CHICAGO — In this video from the AAO meeting, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses the role of AREDS vitamins in slowing the progression of geographic atrophy.

Perceptual learning may offer sustained visual acuity improvements in keratoconus patients, according to a study published in the American Journal of Ophthalmology.

Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in patients with X-linked retinitis pigmentosa, according to a presentation at the FLORetina-ICOOR meeting.

Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, improved best corrected visual acuity at 6 months and maintained a strong safety profile, according to a press release from Emmecell.

Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.